☆ 4.3 Article

Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica

MULTIPLE SCLEROSIS JOURNAL (2022)

Related references

Note: Only part of the references are listed.

Letter Medicine, General & Internal

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab

Sridhar Chilimuri et al.

Summary: Vaccines play a crucial role in ending the COVID-19 pandemic, but their safety and efficacy in multiple sclerosis patients receiving immunosuppressive therapies is not well-documented. Patients on B cell depleting therapy like ocrelizumab show a weakened vaccine response.

VACCINES (2021)

Add to Collection

Article Clinical Neurology

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

Maria Pia Sormani et al.

Summary: This study evaluated the impact of disease-modifying therapies on Covid-19 severity in patients with multiple sclerosis through a pooled-analysis of two large cohorts. The results showed that anti-CD20 therapies were significantly associated with severe Covid-19, while interferon indicated a decreased risk.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology